0000000000305907

AUTHOR

Antonio De La Cuesta

showing 2 related works from this author

Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2019

The Collaborative Working Group “Noma Project Team”.

0301 basic medicinelcsh:Immunologic diseases. Allergycritical limb ischemiaCell typecost-effectivecell-based therapyImmunologyBioinformaticsCell therapy03 medical and health sciences0302 clinical medicineImmunology and AllergyMedicineOriginal Researchclinical trialsdiabetesbusiness.industryMesenchymal stem cellType 2 Diabetes MellitusCritical limb ischemiacellular medicamentsClinical trial030104 developmental biologyStem cellmedicine.symptombusinesslcsh:RC581-607030215 immunologyAdult stem cell
researchProduct

Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2020

[This corrects the article DOI: 10.3389/fimmu.2019.01151.].

lcsh:Immunologic diseases. Allergycritical limb ischemiamedicine.medical_specialtyclinical trialsdiabetesbusiness.industrycost-effectivecell-based therapyImmunologyType 2 Diabetes MellitusCorrectionCritical limb ischemiamedicine.diseasecellular medicamentsCell therapyClinical trialDiabetes mellitusInternal medicinemedicineImmunology and Allergymedicine.symptombusinesslcsh:RC581-607
researchProduct